

## DAFTAR KEPUSTAKAAN

1. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. *Ann Transl Med.* 2016;4(13):1–12.
2. Nansseu JR, Assah F, Petnga S, Kameni BS, Donald H, Tene F, *et al.* Assessing the global risk of cardiovascular disease among a group of university students : population-based cross-sectional study in. 2019;1–9.
3. WHO. Cardiovascular diseases (CVDs). 17 May. 2017 [cited 2019 Oct 9]. Available from: [https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
4. Ilmi HS, Syukri M, Efrida. Hubungan Faktor Risiko yang dapat Dimodifikasi dengan Kejadian Penyakit Jantung Koroner di RS Dr . M . Djamil Padang. *JKA.* 2015;4(2):369–75. Available from: <http://jurnal.fk.unand.ac.id>
5. World Health Organization 2018. Obesity and overweight. diakses 9 oktober 2019, <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>
6. Chrostowska M, Szyndler A, Hoffmann M, Narkiewicz K. Impact of obesity on cardiovascular health. *Best Pract Res Clin Endocrinol Metab.* 2013;27(2):147–56.
7. Centers for Disease Control and Prevention 2017. Adult Body Mass Index (BMI). diakses 9 oktober 2019, <https://www.cdc.gov/obesity/adult/defining.html>
8. International Association for the study of obesity. The Asia-Pacific perspective: redefining obesity and its treatment. Geneva, Switzerland: World Health Organization; 2000. p. 20. 2000. p. 8–45.
9. Caballero B. Humans against Obesity: Who Will Win? *Adv Nutr.* 2019;10:S4–9.
10. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. *Metabolism .* 2019;92:6–10.
11. Badan penelitian dan pengembangan kesehatan. Riset Kesehatan Dasar (RISKESDAS) 2018. Laporan Nasional 2013. 2013. 223-30.
12. Klop B, Elte JWF, Cabezas MC. Dyslipidemia in Obesity: Mechanisms and Potential Targets. *Nutrients.* 2013;5(4):1218–40.
13. Zhou C, Peng H, Yuan J, Lin X, Zha Y, Chen H. Visceral, general, abdominal adiposity and atherogenic index of plasma in relatively lean hemodialysis patients. *BMC Nephrol.* 2018;19(1):3–9.
14. Zhu X, Yu L, Zhou H, Ma Q, Zhou X, Lei T, *et al.* Atherogenic index of

plasma is a novel and better biomarker associated with obesity: A population-based cross-sectional study in China. *Lipids Health Dis.* 2018;17(1):1–6.

15. Neeland IJ, Poirier P, Després JP. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. *Circulation.* 2018;137(13):1391–406.
16. Bo MS, Cheah WL, Lwin S, Moe Nwe T, Win TT, Aung M. Understanding the Relationship between Atherogenic Index of Plasma and Cardiovascular Disease Risk Factors among Staff of an University in Malaysia. *J Nutr Metab.* 2018;2018(2015).
17. Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi S. Atherogenic index of plasma, Castelli risk index and Atherogenic coefficient - New Parameters in assessing Cardiovascular Risk. *Int J Pharm Biol Sci* [Internet]. 2013;3(3):359–64.
18. Sharma SB, Garg S. Small dense LDL: Risk factor for coronary artery disease (CAD) and its therapeutic modulation. *Indian J Biochem Biophys.* 2012;49(2):77–85.
19. Zalejska-Fiolka J, Hubková B, Birková A, Veliká B, Puchalska B, Kasperczyk S, *et al.* Prognostic value of the modified atherogenic index of plasma during body mass reduction in Polish obese/overweight people. *Int J Environ Res Public Health.* 2019;16(1).
20. Chhezom K, Arslan MI, Hoque MM, Biswas SK. Biomarkers of cardiovascular and metabolic diseases in otherwise healthy overweight subjects in Bangladesh. *Diabetes Metab Syndr Clin Res Rev* [Internet]. 2017;11(2016):S381–4.
21. Hartopo AB, Arso IA, Setianto BY. Low Plasma Atherogenic Index Associated with Poor Prognosis in Hospitalized Patients with Acute Myocardial Infarction. *Acta Med Indones.* 2016;48(2):106–13.
22. WHO Regional Office for Europe. Body mass index - BMI. diakses 9 oktober 2019, <http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi>.
23. Centers for Disease Control and Prevention 2017. diakses 9 oktober 2019, [https://www.cdc.gov/healthyweight/assessing/bmi/adult\\_bmi/index.html#Definition](https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html#Definition).
24. Gonzalez-Campoy JM, Hurley DL, Garvey WT. Clinical Definition of Overweight and Obesity. *Bariatric Endocrinol Eval Manag Adiposity, Adiposopathy Relat Dis.* 2018;vii–viii.
25. World Health Organization 2017. Obesity. diakses 9 Oktober 2019 <https://www.who.int/topics/obesity/en/>

26. Blüher M. Obesity: global epidemiology and pathogenesis. *Nat Rev Endocrinol.* 2019;15(5):288–98.
27. Guyton AC, Hall JE. *Guyton and Hall textbook of medical physiology* 11th edition. Philadelphia, PA: Saunders Elsevier; 2006. p. 161-70.
28. Sugondo S. Obesitas. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. *Buku ajar ilmu penyakit dalam jilid III*. Jakarta: Penerbitan departemen ilmu penyakit dalam FK UI; 2009. p. 1973.
29. Apovian CM. Obesity: definition, comorbidities, causes, and burden. *Am J Manag Care.* 2016;22(7):s176–85.
30. Islam QT, Reza IB. Obesity – A global Burden, Crucial Problem for the Society. *Bangladesh J Med.* 2018;29(2):75–83.
31. Kaila B, Raman M. Obesity: A review of pathogenesis and management strategies. *Can J Gastroenterol.* 2008;22(1):61–8.
32. N R, Redinger M. The Pathophysiology of Obesity and Its Clinical Manifestations. *Gastroenterol Hepatol (N Y) [Internet].* 2007;856–863.
33. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: Pathophysiology and Management. *J Am Coll Cardiol.* 2018;71(1):69–84.
34. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. *N Engl J Med.* 2017;376(3):254–66.
35. Pozza C, Isidori AM. What's Behind the Obesity Epidemic. *Imaging Bariatr Surg.* 2018;1–8.
36. Franssen R, Monajemi H. Obesity and Dyslipidemia. *Med Clin NA.* 2011;95(5):893–902.
37. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. *Arch Med Res.* 2005;36(3):232–40.
38. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, *et al.* Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. *Circulation.* 2011;123(20):2292–333.
39. Choi HY, Hafiane A, Schwertani A, Genest J. High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. *Can J Cardiol.* 2017;33(3):325–33.
40. Wang H, Peng DQ. New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. *Lipids Health Dis.* 2011;10:1–10.
41. Jim EL. Metabolisme Lipoprotein. *J Biomedik.* 2014;5(3).
42. Ortega-Loubon C, Fernández-Molina M, Singh G, Correa R. Obesity and its cardiovascular effects. *Diabetes Metab Res Rev.* 2019;35(4).



43. TY P. Pola kadar glukosa dara puasa, kolesterol, dan trigliserida pada penderita sirosis hati. Semarang: Fakultas Kedokteran Universitas Diponegoro; 2000.
44. Syafitri V, Arnelis E. Gambaran Profil Lipid Pasien Perlemakan Hati Non-Alkoholik. JKA. 2015;4(1):274–8.
45. Decroli E, Yerizel E, Andam Astari N. Gambaran NAFLD pada Pasien dengan Sindrom Metabolik di Artikel Penelitian. JKA. 2015;4(2):441–6.
46. Ahmad N, Bandu N, Artha DE. Gambaran Dislipidemia Pada Penderita Gagal Ginjal Kronik Di Rumah Sakit Dr. Wahidin Sudirohusodo Makassar. J Media Laboran. 2018;8:44–50.
47. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: Nearly as large as smoking. *Circulation*. 2005;111(20):2684–98.
48. Niroumand S, Khajedaluae M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodae G, *et al*. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. *Med J Islam Repub Iran*. 2015;29(1):627–35.
49. Dahlan MS. Statistik untuk kedokteran dan kesehatan edisi 5. Jakarta: Penerbit Salemba Medika : 2012. p.167-9.
50. Wati LW, Fanani M, Herawati E. Perbedaan Derajat Depresi antara Siswi yang Memiliki Berat Badan Normal dengan Berat Badan Berlebih di SMA Muhammadiyah 1 Surakarta. Dr Diss Univ Muhammadiyah Surakarta. 2016.
51. Fernando ML. Gambaran citra tubuh pada wanita dewasa awal yang mengalami obesitas. *J Ilm Psikol Terap*. 2019;7(1):101.
52. ATP III Guidelines At-A-Glance Quick Desk Reference. National Institutes of Health. 2001. Available from: <https://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf>
53. Winarsi H, Wijayanti SPM, Purwanto A. Profil Lipid, Peroksidasi Lipid, dan Status Inflamatif Wanita Penderita Sindrom Metabolik. *Kesmas Natl Public Heal J*. 2011;5(5):212.
54. Sari DRK. Perbedaan Senam Aerobik Intensitas Ringan dan Sedang terhadap Perbaikan Dislipidemia pada Wanita Menopause. *J Kesehat*. 2013;187–98.
55. Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D. Triglycerides and HDL cholesterol: stars or second leads in diabetes. *Diabetes Care*. 2009;32 Suppl 2.
56. Onat A, Can G, Kaya H, Hergenç G. —Atherogenic index of plasma (log<sub>10</sub> triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. *J Clin Lipidol*. 2010;4(2):89–98.

57. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Panduan Tata laksana Displidemia 2017. 2017. 1–96 p.
58. Kanthe PS, Patil BS, Bagali S, Deshpande A, Shaikh GB, Aithala M. Atherogenic index as a predictor of cardiovascular risk among women with different grades of obesity. *Int J Collab Res Intern Med Public Heal.* 2012;4(10):1767–74.
59. Yildiran H, Acar TN, Koksall E, Gezmen KM, Akbulut G, Bilici S, *et al.* The association of anthropometric measurements and lipid profiles in Turkish hypertensive adults. *Afr Health Sci.* 2011;11(3):407–13.
60. Hasan BF, Alhuda N, Ibrahim K, Hameedi PBH. Atherogenic Index of Plasma and Insulin Resistance in Obese Diabetic Patients. *Int J Sci Res.* 2016;5(5):2408–12.
61. Dobiášová M. [AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice]. *Vnitr Lek.* 2006 Jan;52(1):64—71.
62. Latifa A. *Digital Repository Universitas Jember.* 2015;4(1):27.
63. Dobiášová M. Atherogenic impact of lecithin-cholesterol acyltransferase and its relation to cholesterol esterification rate in HDL (FERHDL) and AIP [log(TG/HDL-C)] biomarkers: The butterfly effect? *Physiol Res.* 2017;66(2):193–203.



